by | May 1, 2024 | Publications
Cancer Med. 2024 May;13(9):e7177. doi: 10.1002/cam4.7177. ABSTRACT OBJECTIVE: To evaluate the effectiveness, safety, and convenience of in-class transition (iCT) from intravenous bortezomib-based induction to ixazomib-based oral regimens. METHODS: This retrospective...
by | May 1, 2024 | Publications
Int J Clin Oncol. 2024 Apr 30. doi: 10.1007/s10147-024-02531-1. Online ahead of print. NO ABSTRACT PMID:38687406 | DOI:10.1007/s10147-024-02531-1
by | May 1, 2024 | Publications
Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-3333. Online ahead of print. ABSTRACT PURPOSE: Bispecific antibodies (BsAbs) directed against B-cell maturation antigen (BCMA; teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce...
by | May 1, 2024 | Publications
Leukemia. 2024 Apr 30. doi: 10.1038/s41375-024-02247-1. Online ahead of print. NO ABSTRACT PMID:38688994 | DOI:10.1038/s41375-024-02247-1
by | May 1, 2024 | Publications
Cureus. 2024 Apr 14;16(4):e58224. doi: 10.7759/cureus.58224. eCollection 2024 Apr. ABSTRACT Pathological fractures commonly occur in patients with metastatic bone diseases, particularly multiple myeloma. The current optimal management for metastatic pathological...
by | May 1, 2024 | Publications
Front Oncol. 2024 Apr 16;14:1390105. doi: 10.3389/fonc.2024.1390105. eCollection 2024. ABSTRACT Multiple myeloma (MM) is an incurable malignant plasma cell disorder characterized by the infiltration of clonal plasma cells in the bone marrow compartment. Gene...